National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda.
Division of Infectious Diseases, Department of Medicine, University of Minnesota.
J Infect Dis. 2019 May 24;219(12):1963-1968. doi: 10.1093/infdis/jiz042.
Lactoferrin modulates mucosal immunity and targets mechanisms contributing to inflammation during human immunodeficiency virus disease. A randomized placebo-controlled crossover clinical trial of recombinant human (rh) lactoferrin was conducted among 54 human immunodeficiency virus-infected participants with viral suppression. Outcomes were tolerability, inflammatory, and immunologic measures, and the intestinal microbiome. The median age was 51 years, and the median CD4+ cell count was 651/µL. Adherence and adverse events did not differ between rh-lactoferrin and placebo. There was no significant effect on plasma interleukin-6 or D-dimer levels, nor on monocyte/T-cell activation, mucosal integrity, or intestinal microbiota diversity. Oral administration of rh-lactoferrin was safe but did not reduce inflammation and immune activation. Clinical Trials Registration: NCT01830595.
乳铁蛋白调节黏膜免疫，并针对人类免疫缺陷病毒疾病期间导致炎症的机制。在 54 名病毒抑制的人类免疫缺陷病毒感染参与者中，进行了重组人（rh）乳铁蛋白的随机安慰剂对照交叉临床试验。结果是耐受性、炎症和免疫指标以及肠道微生物组。中位年龄为 51 岁，中位 CD4+细胞计数为 651/µL。rh-乳铁蛋白和安慰剂之间的依从性和不良事件没有差异。对血浆白细胞介素 6 或 D-二聚体水平、单核细胞/ T 细胞活化、黏膜完整性或肠道微生物多样性均无显著影响。口服 rh-乳铁蛋白是安全的，但不能减轻炎症和免疫激活。临床试验注册：NCT01830595。
